View Older Stories View More Recent Stories

Jun 14, 2016 07:02AM VolitionRx Publishes Study Confirming Stability of Circulating Cell-Free Nucleosomes as Biomarkers for Cancer Diagnostic Blood Tests
May 31, 2016 09:16AM VolitionRx to Present at Two Upcoming Conferences in June
May 19, 2016 07:00AM VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting
May 13, 2016 07:00AM VolitionRx Announces First Quarter 2016 Financial Results and Business Update
May 9, 2016 07:00AM VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET
Apr 20, 2016 09:14AM VolitionRx (VNRX) Says NuQ Biomarker Assay Detected 71% of Early Stage I Prostate Cancer Cases at 93% Specificity
Apr 20, 2016 09:00AM VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test
Apr 14, 2016 07:00AM VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer
Apr 11, 2016 07:00AM VolitionRx to Participate in 2016 Morgan Stanley Healthcare Insight Series
Apr 8, 2016 07:00AM VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study
Apr 7, 2016 07:08AM VolitionRx Announces CE Marks for Two NuQ® Blood Assays for Detection of Colorectal Cancer
Mar 23, 2016 11:30AM VolitionRx Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
Mar 18, 2016 09:31AM VolitionRx Limited (VNRX) Prices 3.77M Common Stock Offering at $3.25/Share
Mar 18, 2016 09:29AM VolitionRx Announces Pricing of Public Offering of Common Stock
Mar 17, 2016 04:02PM Volitionrx Limited (VNRX) to Offer Shares of Common Stock
Mar 17, 2016 04:01PM VolitionRx Announces Proposed Public Offering of Common Stock
Mar 11, 2016 07:35AM VolitionRx Announces Full Year 2015 Financial Results and Business Update
Mar 9, 2016 08:30AM VolitionRx Schedules Full-Year 2015 Earnings Conference Call and Business Update for Friday, March 11, 2016 at 8:30am ET
Mar 9, 2016 07:19AM VolitionRx (VNRX) Says Preliminary Data Shows 86% Accuracy in Detecting IPF Using Blood Test
Mar 9, 2016 07:00AM Preliminary Data Demonstrates 86% Accuracy in Detecting Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease
Feb 17, 2016 07:27AM Volitionrx Limited (VNRX) Issues Positive Data from NuQ Blood-Based Biomarker Assay Effectiveness Trial
Feb 17, 2016 07:00AM VolitionRx Demonstrates 75% Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ® Blood Test
Feb 4, 2016 07:00AM VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection
Feb 2, 2016 07:00AM VolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK
Jan 28, 2016 07:00AM VolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests
Jan 13, 2016 07:00AM VolitionRx Releases Annual Shareholder Update Letter
Jan 5, 2016 07:00AM VolitionRx Announces Dr. Jason Terrell's Transition to Full-Time Status as Chief Medical Officer and Head of U.S. Operations
Jan 4, 2016 07:00AM VolitionRx Granted Its Third U.S. Patent
Dec 8, 2015 07:00AM VolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study
Nov 30, 2015 07:00AM VolitionRx to Present at LD Micro Conference on December 3 in Los Angeles
Nov 19, 2015 07:00AM VolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy
Nov 17, 2015 09:00AM VolitionRx Granted Its Second U.S. Patent
Nov 12, 2015 07:00AM VolitionRx to Present at Two Conferences in November
Nov 4, 2015 06:30AM VolitionRx Announces Third Quarter 2015 Financial Results and Business Update
Oct 30, 2015 07:00AM VolitionRx Schedules Third Quarter 2015 Earnings Conference Call and Business Update for Wednesday, November 4, 2015 at 8:30am ET
Oct 22, 2015 07:00AM VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study
Oct 12, 2015 07:00AM VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics
Sep 22, 2015 07:00AM VolitionRx Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer
Sep 10, 2015 07:00AM VolitionRx Granted Its First U.S. Patent
Sep 9, 2015 08:00AM VolitionRx Demonstrates NuQ(R) Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial
Sep 2, 2015 08:00AM VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015
Sep 1, 2015 08:00AM VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015
Aug 17, 2015 08:00AM VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer
Aug 11, 2015 06:30AM VolitionRx Announces Second Quarter 2015 Financial Results and Business Update
Aug 5, 2015 08:00AM VolitionRx Schedules Second Quarter 2015 Earnings Conference Call and Business Update for Tuesday, August 11, 2015 at 8:30am ET
Aug 3, 2015 08:00AM VolitionRx to Present at Wedbush PacGrow Healthcare Conference
Jul 27, 2015 08:00AM VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs
Jul 8, 2015 08:00AM VolitionRx CSO Dr. Jake Micallef to Present Scientific Webinar
Jul 6, 2015 08:18AM VolitionRx Expands Scientific Advisory Board
Jun 23, 2015 08:00AM VolitionRx Partners with Two Market Access Consulting Agencies to Support Market Access of NuQ(R) Colorectal Cancer Tests in Europe
View More Recent Stories View Older Stories